And just one more thing: Peter Falk was a longtime cancer survivor

Article

You've probably heard that actor Peter Falk died last week at age 83. Best known for his television persona Columbo, Falk was also an eight-decade cancer survivor. When he was 3 years old, his preschool teacher noticed he cocked his head in an unusual way whenever he looked at something, so she recommended he see a doctor. Young Peter received a diagnosis of retinoblastoma, a rare form of eye cancer that must be treated quickly because it develops rapidly. Within two days, his tumor was removed along with his right eye. He used a prosthetic eye for the rest of his life--always to his advantage. In his autobiography, Falk recounted how, as a teenager, he used his glass eye to get laughs. Once while playing baseball in high school, Falk was called out at third base. "It was a bad call," Falk said. "I was clearly safe. I knew it and everybody in the stands knew it. They sat so close to the field, they could see and hear everything. In front of everyone, I whipped out my eye and handed it to the umpire: 'You'll do better with this one.' Talk about getting a laugh. I got a roar. Even the guys on the other team were rolling in the grass." Later, Falk used his signature squint as part of nearly every eccentric character he played, including Columbo, the quirky detective who was always seen wearing a rumpled raincoat and smoking stumpy cigars. In addition to being twice nominated for an Academy Award, Falk won five Emmys and a Golden Globe. In recent years, he had been treated for dementia and Alzheimer's disease.

Related Videos
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL